ES2535461T3 - Método de tratamiento de la enfermedad por almacenamiento de glucógeno - Google Patents

Método de tratamiento de la enfermedad por almacenamiento de glucógeno

Info

Publication number
ES2535461T3
ES2535461T3 ES09794820.2T ES09794820T ES2535461T3 ES 2535461 T3 ES2535461 T3 ES 2535461T3 ES 09794820 T ES09794820 T ES 09794820T ES 2535461 T3 ES2535461 T3 ES 2535461T3
Authority
ES
Spain
Prior art keywords
glucosidase
glycogen
human acid
gaa
gsd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09794820.2T
Other languages
English (en)
Spanish (es)
Inventor
Yuan-Tsong Chen
Priya Kishnani
Baodong Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Application granted granted Critical
Publication of ES2535461T3 publication Critical patent/ES2535461T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES09794820.2T 2008-07-08 2009-07-08 Método de tratamiento de la enfermedad por almacenamiento de glucógeno Active ES2535461T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12961208P 2008-07-08 2008-07-08
US129612P 2008-07-08
PCT/US2009/003993 WO2010005565A2 (en) 2008-07-08 2009-07-08 Method of treating glycogen storage disease

Publications (1)

Publication Number Publication Date
ES2535461T3 true ES2535461T3 (es) 2015-05-11

Family

ID=41507636

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09794820.2T Active ES2535461T3 (es) 2008-07-08 2009-07-08 Método de tratamiento de la enfermedad por almacenamiento de glucógeno

Country Status (12)

Country Link
US (5) US9050333B2 (pt)
EP (1) EP2318037B1 (pt)
CY (1) CY1116216T1 (pt)
DK (1) DK2318037T3 (pt)
ES (1) ES2535461T3 (pt)
HR (1) HRP20150414T1 (pt)
HU (1) HUE025212T2 (pt)
PL (1) PL2318037T3 (pt)
PT (1) PT2318037E (pt)
SI (1) SI2318037T1 (pt)
SM (1) SMT201500103B (pt)
WO (1) WO2010005565A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10017581B2 (en) 2013-02-20 2018-07-10 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
US20180326021A1 (en) * 2015-08-31 2018-11-15 Duke University Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
IL299325A (en) 2016-09-12 2023-02-01 Inst Nat Sante Rech Med Variants of acid alpha glucosidase and their uses
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
US20180207193A1 (en) * 2017-01-24 2018-07-26 Duke University Compositions and methods for improving enzyme replacement therapy for lysosomal storage diseases
BR112019025224A2 (pt) * 2017-05-31 2020-12-08 Ultragenyx Pharmaceutical Inc. Terapêutica para doença de armazenamento de glicogênio tipo iii

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2353522A1 (en) * 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Treatment of pompe's disease
PT1301201E (pt) 2000-07-18 2007-03-30 Univ Duke Tratamento da doença de armazenamento de glicogénio tipo ii

Also Published As

Publication number Publication date
DK2318037T3 (en) 2015-05-04
HRP20150414T1 (hr) 2015-06-19
SMT201500103B (it) 2015-07-09
US9850474B2 (en) 2017-12-26
EP2318037A4 (en) 2012-03-07
US10647969B2 (en) 2020-05-12
US20180073003A1 (en) 2018-03-15
HUE025212T2 (en) 2016-03-29
US9050333B2 (en) 2015-06-09
WO2010005565A3 (en) 2010-05-14
EP2318037A2 (en) 2011-05-11
PL2318037T3 (pl) 2015-07-31
EP2318037B1 (en) 2015-01-28
PT2318037E (pt) 2015-05-20
US11214782B2 (en) 2022-01-04
US20110104187A1 (en) 2011-05-05
WO2010005565A2 (en) 2010-01-14
US20200299663A1 (en) 2020-09-24
SI2318037T1 (sl) 2015-07-31
CY1116216T1 (el) 2017-02-08
US20160122733A1 (en) 2016-05-05
US20220106579A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
ES2535461T3 (es) Método de tratamiento de la enfermedad por almacenamiento de glucógeno
JP7395693B2 (ja) 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
AU2019204056B2 (en) Cns delivery of therapeutic agents
ES2700865T3 (es) Tratamiento de glucogenosis de tipo II
CN103260637B (zh) 乙酰肝素n-硫酸酯酶cns递送的方法和组合物
TWI609694B (zh) 溶酶體酵素之腦脊髓膜內遞送及其醫療用途
ES2679374T3 (es) Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
CA2149776C (en) Use of methioninase as an antitumor agent in anti-methionine chemotherapy
BR122017015900A2 (pt) ácido nucleico e células
EP1981546A2 (en) Enzyme replacement therapy for treating lysosomal storage diseases
US20220251526A1 (en) Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
KR20240042110A (ko) 안정화된 알파-갈락토시다제를 이용하는 파브리의 치료를 위한 치료적 요법
WO2024036044A1 (en) Compositions and methods for treating and preventing metabolic disorders
EA043224B1 (ru) Составы, содержащие рекомбинантную кислую альфа-глюкозидазу
BR112012033205A2 (pt) uso de uma composição compreendendo agentes terapêuticos para liberação ao sistema nervoso central